The European Commission approves the use of Lecanemab, a monoclonal antibody medication that targets amyloid

Context: China–United States trade war.

The European Commission approves the use of Lecanemab, a monoclonal antibody medication that targets amyloid beta peptides, to treat the early stages of Alzheimer's disease via intravenous therapy. This is the first drug to be approved to treat the disease in Europe, and was approved by the Food and Drug Administration in the United States in 2023. [https://www.dw.com/en/lecanemab-alzheimers-therapy-approved-in-europe/a-72253945 (DW)]

Event summary via Wikipedia Current Events (2025-04-15).